The 2025 ASCO Annual Meeting showcased new data on therapies for chronic lymphocytic leukemia, including zanubrutinib, acalabrutinib, and liso-cel.
The post New Data on CLL Therapies Presented at the 2025 ASCO Annual Meeting first appeared on Physician’s Weekly.
